Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: Ariana Resources, Michelmersh, ReNeuron...

Mon, 12th Jul 2010 08:31

Shares in Ariana Resources rallied after the Turkey-focused gold miner announces the completion of its joint venture agreement with Proccea to develop the Red Rabbit Project in western Turkey.The group said results from the recent resource drilling programme are expected shortly. Managing director Kerim Sener said: "This JV has now put us firmly on the path towards becoming the next gold producer in Turkey, and has created a solid set of foundations to spur the growth of your company.""We are delighted to be in partnership with a strong and competent JV partner and we look forward to adding further value to our assets via this JV."Brickmaker Michelmersh's terracotta and faience production business has won six supply contracts for high profile projects in London. Products made by Hathern Terracotta, launched in August last year, will be used in the Savoy in the Strand, "a world renowned department store in Knightsbridge", the V&A in South Kensington, new Apple Store in Covent Garden, homes in St John's Wood and Barons Court Underground Station. New tests carried out by stem cell therapy group ReNeuron suggest CTX stem cells may play a role in promoting the functional recovery of stroke patients and suppress the inflammatory response associated with brain damage, aiding the natural healing processes in the brain."These latest findings further illustrate and potentially explain the potency of the CTX cells in assisting the body's own repair mechanisms in vascular conditions such as stroke and peripheral arterial disease, and suggest the potential utility of the cells to treat a much wider range of inflammatory diseases," said chief scientific officer John Sinden.TanzaniteOne has sold 191,673 carats of rough tanzanite at $13.4/carat during its third official sale of 2010 in Dubai, bringing in revenue of $2.57m.Sales in May and June have lifted second quarter revenue to $5.4m, up 80% on the first three months of the year and the best quarterly performance in two years. First half revenue rose to $8.4m."This extremely encouraging quarterly revenue has surpassed both our internal recovery projections as well as market expectations," said boss Bernard Olivier.Shares in Sweden-focused miner Beowulf Mining moved ahead after it revealed that initial results from its drilling programme at its wholly-owned Kallak iron ore deposit have shown commercial grades across the deposit.Shares in Best of the Best, which displays luxury cars as competition prizes in airports, climbed after results that suggest it is weathering economic difficulties. In the year to April 30, pre-tax profits slipped to £0.48m from £0.52m as revenues eased to £7.3m from £7.46m.Henderson Morley is still waiting for KMS to come up with the cash to complete the purchase of the rights to its ionic contra-viral therapy human portfolio and has granted a further extension until 14 July (Wednesday).Indian power supplier KSK Power's profits surged last year $76.9m from $8.6m, which included $31.8m (2009: $1.0m) from currency gains. Operating profit rose 118% to $26.3m. "With the commencement of power generation from VS Lignite Power and the first unit at Wardha Warora project, the anticipated new cash flow cycle has now begun," said KSK. "We remain on course to meet market expectations in 2011 and are confident in our ability to meet our longer term goals," it added.Kazakhstan focused Max Petroleum reports a recent study by Ryder Scott on the company's Blocks A&E licence ares showed total risked mean recoverable resources estimated at 1,100 million barrels of oil equivalent. Total unrisked mean recoverable resources estimated at 5,358 million barrels, distributed within a probable range (P90 to P10) of 2,004 million barrels to 8,847 million barrels."We are pleased that Ryder Scott's assessment of our portfolio, like our own, recognizes the significant potential of both the pre and post-salt prospects and leads we have identified on Blocks A & E," Jim Jeffs, executive co-chairman said.Canadian independent oil and gas company Ithaca Energy said it has signed and completed the senior secured borrowing base facility agreement for up to $140m announced on 22 April.Perpetual Income & Growth Investment Trust saw its net asset value per share total return slide 5.4% in the second quarter, a performance which still outshone that of the FTSE All-Share index, which fell 11.8% over the same period. Total gross assets at the end of June stood at £550.6m, down from £587.4m.Value & Income Trust, which invests in higher yielding, less fashionable areas of the UK commercial property and quoted equity markets, saw its net asset value (NAV) per share slide to 212.5p with debt at par value in the second quarter from 231.8p at the end of the first quarter.
More News
29 Nov 2019 16:07

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
23 Oct 2019 15:50

ReNeuron presents new data on CTX stem cell platform

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Wednesday that new data relating to its CTX stem cell platform was being presented at the 27th Annual Congress of the European Society of Gene and Cell Therapy in Barcelona.

Read more
23 Oct 2019 09:32

ReNeuron Shares Jump As Lead Cell Line Shows Further Potential

ReNeuron Shares Jump As Lead Cell Line Shows Further Potential

Read more
2 Oct 2019 15:15

ReNeuron Reports Mixed Results For Retinitis Pigmentosa Trial

ReNeuron Reports Mixed Results For Retinitis Pigmentosa Trial

Read more
21 Aug 2019 11:49

ReNeuron boosts scientific advisory board with three appointments

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced the appointment of professor Robert MacLaren, Dr Sally Temple and Dr José-Alain Sahel to its scientific advisory board on Wednesday.

Read more
14 Aug 2019 15:35

ReNeuron's New Cardiff University Venture Gets Research Grant

(Alliance News) - ReNeuron Group PLC on Wednesday said a new venture with Cardiff University has secured a UK government grant to research and develop new treatments for hard-to-target disorders a

Read more
14 Aug 2019 11:16

ReNeuron enters grant-funded partnership with University of Cardiff

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group is partnering with the University of Cardiff under a new grant-funded collaboration utilising its exosome-based drug delivery technology platform, it announced on Wednesday.

Read more
16 Jul 2019 12:16

ReNeuron Secures Patents For Its Exosome Technology Platform

(Alliance News) - ReNeuron Group PLC on Tuesday said it has expanded its intellectual property estate via the grant of patents, covering its exosome technology platform.The cell-based said

Read more
11 Jul 2019 11:36

ReNeuron Annual Loss Narrows On Finance Income And Licence Fee

(Alliance News) - ReNeuron Group PLC on Thursday said its loss narrowed in its most recent financial year after it received an exclusivity fee and increased finance income.Shares in were at

Read more
14 Jun 2019 15:49

ReNeuron wins 'Breakthrough of the Year' at European Mediscience Awards

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group has won the 'Breakthrough of the Year' award at the 2019 European Mediscience Awards, it announced on Friday.

Read more
8 May 2019 11:19

ReNeuron Expects Annual Results In Line With Views After Progress

LONDON (Alliance News) - ReNeuron Group PLC on Wednesday said it expects its annual results to be in line with the board's expectations as it made progress on several clinical cell-based also

Read more
8 May 2019 08:53

ReNeuron advances blindness and stroke therapy candidates

(Sharecast News) - Therapeutics outfit ReNeuron continued to trade in line with expectations throughout its recently wrapped up trading year, advancing both its human retinal progenitor cell therapy candidate and its CTX cell therapy candidate.

Read more
26 Apr 2019 12:09

ReNeuron upbeat on early data from retinitis pigmentosa trials

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced updated positive preliminary data in its ongoing phase 1 and 2a clinical trial of its human retinal progenitor cell (hRPC) therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP), on Friday.

Read more
26 Apr 2019 09:58

ReNeuron Reports Positive Test Results For Blindness Treatment Therapy

LONDON (Alliance News) - ReNeuron Group PLC on Friday reported positive trial results for its human retinal progenitor cell therapy candidate for treating blindness-causing disease retinitis in up

Read more
11 Apr 2019 18:24

DIRECTOR DEALINGS: ReNeuron Chair And Other Board Members Buy Shares

LONDON (Alliance News) - ReNeuron Group PLC said a number of directors purchased shares on Thursday, including Non-Executive Chair John Berriman who bought 80,000 shares at 225 pence Thursday, in

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.